当前位置:首页 - 行情中心 - 天新药业(603235) - 财务分析 - 现金流量表

天新药业

(603235)

  

流通市值:40.35亿  总市值:120.13亿
流通股本:1.47亿   总股本:4.38亿

现金流量表

报告期2024-03-312023-12-312023-09-302023-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金385,278,707.631,732,223,928.591,406,321,475.271,003,838,941.68
收到的税费返还9,760,359.6571,238,997.3138,632,642.3433,706,783.3
收到其他与经营活动有关的现金24,110,001.43234,202,764.23127,065,455.6385,589,358.57
经营活动现金流入的平衡项目0000
经营活动现金流入小计419,149,068.712,037,665,690.131,572,019,573.241,123,135,083.55
购买商品、接受劳务支付的现金147,603,093.75721,501,946.72552,237,547.43434,507,452.72
支付给职工以及为职工支付的现金146,723,643.42381,397,460.39310,405,257.53220,726,550.15
支付的各项税费24,200,450.78126,369,929.189,848,827.2436,260,719.73
支付其他与经营活动有关的现金6,708,160.1879,183,854.3334,563,88930,220,059.28
经营活动现金流出的平衡项目0000
经营活动现金流出小计325,235,348.131,308,453,190.54987,055,521.2721,714,781.88
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额93,913,720.58729,212,499.59584,964,052.04401,420,301.67
二、投资活动产生的现金流量:
收到的其他与投资活动有关的现金143,896,761.182,030,454,292.841,565,467,025.671,245,152,900.45
投资活动现金流入的平衡项目0000
投资活动现金流入小计143,896,761.182,030,454,292.841,565,467,025.671,245,152,900.45
购建固定资产、无形资产和其他长期资产支付的现金115,363,732.59535,600,089.46349,615,198.35206,060,959.97
投资支付的现金--9,228.88-
支付其他与投资活动有关的现金147,509,9901,798,000,0001,330,000,131.111,010,000,000
投资活动现金流出的平衡项目0000
投资活动现金流出小计262,873,722.592,333,600,089.461,679,624,558.341,216,060,959.97
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-118,976,961.41-303,145,796.62-114,157,532.6729,091,940.48
三、筹资活动产生的现金流量:
取得借款收到的现金120,000,000100,000,000100,000,000100,000,000
筹资活动现金流入平衡项目0000
筹资活动现金流入小计120,000,000100,000,000100,000,000100,000,000
分配股利、利润或偿付利息支付的现金834,871.99312,423,522.21286,261,210.59285,115,855.55
支付其他与筹资活动有关的现金28,417,490.563,171,139.22-1,856,310
筹资活动现金流出平衡项目0000
筹资活动现金流出小计29,252,362.55315,594,661.43286,261,210.59286,972,165.55
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额90,747,637.45-215,594,661.43-186,261,210.59-186,972,165.55
四、汇率变动对现金及现金等价物的影响2,297,449.7927,767,507.2145,539,96450,258,733.84
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额67,981,846.41238,239,548.75330,085,272.78293,798,810.44
加:期初现金及现金等价物余额2,307,768,991.532,069,529,442.782,069,529,442.782,069,529,442.78
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额2,375,750,837.942,307,768,991.532,399,614,715.562,363,328,253.22
补充资料:
净利润-475,853,298.64-329,956,160.32
资产减值准备-12,363,832.71-914,329.71
固定资产和投资性房地产折旧-131,931,846.48-65,279,491.18
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-131,931,846.48-65,279,491.18
无形资产摊销-3,917,890.71-1,529,271.61
长期待摊费用摊销-1,385,837.04-692,918.52
固定资产报废损失-89,737.68-51,371.15
财务费用--25,667,728.35--59,521,359.47
投资损失--2,074,607.89--1,179,285.5
递延所得税--22,525,209.15--6,170,722.71
其中:递延所得税资产减少--22,525,209.15--6,170,722.71
存货的减少--20,506,310.6-75,351,065.22
经营性应收项目的减少-7,149,428.43-30,209,330.79
经营性应付项目的增加-82,919,684.51--72,208,034.83
其他-84,631,493.49-36,831,166.22
不涉及现金收支的投资和筹资活动金额其他项目-2,896,890.46--
现金的期末余额-2,307,768,991.53-2,363,328,253.22
减:现金的期初余额-2,069,529,442.78-2,069,529,442.78
公告日期2024-04-302024-04-242023-10-312023-08-26
审计意见(境内)标准无保留意见
TOP↑